Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy

This study looks at whether measuring a patient's 'biological age' (how old the body is functioning compared to actual age) alongside standard frailty assessments can better guide treatment decisions for people newly diagnosed with chronic myeloid leukemia (CML). CML is a type of blood cancer. Patients are treated with drugs called tyrosine kinase inhibitors (TKIs), and this study aims to personalize care based on biological rather than just chronological age. **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with CML in the chronic (early, stable) phase - Your diagnosis was made within the last 3 months - You read and understand French - You have not yet started TKI therapy **You may NOT be eligible if...** - Your CML is in an advanced phase (accelerated or blast phase) - You have already started CML treatment - You are pregnant or breastfeeding - You are under legal guardianship or in judicial custody Talk to your doctor to see if this trial is right for you.